Can Thymosin Alpha-1 Plus Antiviral Drugs Cure Chronic Hepatitis B?

Combining thymosin α1 (Tα1), an immune-boosting peptide, with nucleos(t)ide analog antivirals (NUCs) may be more effective at clearing chronic hepatitis B than either approach alone. While NUCs suppress viral replication and Tα1 can help eliminate viral surface markers (HBsAg and HBeAg) in select patients, the combination leverages both viral suppression and immune activation. Small studies using Tα1 with NUCs showed encouraging results, and clinical trials combining entecavir with Tα1 were underway at the time of publication.

Narrative review summarizing existing clinical trial data on thymosin α1 efficacy in hepatitis B, with a focus on combination therapy approaches using Tα1 alongside nucleoside/nucleotide analogs. The review reanalyzed previous Tα1 monotherapy trials in the context of modern combination therapy strategies.

Chronic hepatitis B infects hundreds of millions of people worldwide, and current antiviral treatments suppress the virus but rarely cure it. A functional cure requires the immune system to clear remaining virus — exactly what thymosin α1 aims to do. This review makes the case that combining immune stimulation with antiviral suppression could achieve what neither approach accomplishes alone: actual resolution of chronic HBV infection.

The hepatitis B cure agenda has gained momentum in recent years, with researchers increasingly recognizing that antiviral suppression alone won't achieve functional cure — the immune system must be re-engaged. Thymosin α1 is one of several immunomodulatory approaches being explored alongside direct-acting antivirals, part of a broader shift toward combination strategies modeled on the successful hepatitis C cure revolution.

The combination therapy evidence cited comes from small studies, not large randomized trials. The review is somewhat advocacy-oriented, making the case for Tα1 combination therapy rather than providing a balanced assessment of all approaches. Clinical trials referenced were anticipated but results were not yet available at publication time. Individual patient response to Tα1 varies considerably.